Find out what our scientists are working on to improve diagnosis, therapy and treatment of lung diseases step by step.
The poor course of the chronic obstructive pulmonary disease could be slowed down with an agent from the azole group. But what is the best way for this agent to reach its target, the lungs?
Can researchers succeed in identifying antibodies and "repair" them with specific therapies? That would be a completely new treatment option for pulmonary fibrosis.
The imaging platform of radiology at Munich University Hospital is breaking new ground in the diagnosis of lung diseases with new techniques and equipment.
The immunoproteasome is responsible for quality control in the cell and could therefore be a starting point for a new biomarker to predict the worsening of COPD.
Fibrotic lung diseases usually progress quickly. Researchers of the CPC-M are investigating a protein which could stop the collagen formation in the lung tissue – and thus the scarring.
In the ALLIANCE study, DZL scientists and physicians try to close gaps in knowledge regarding the pathogenesis and progression of asthma in children.
Interstitial lung diseases in children are an enigma in lung medicine. The Germany-wide chILD-EU study aims to close this gap and systematically search for new therapies.
For the first time, scientists in Bavaria are comprehensively analyzing how COPD patients are treated – and how this affects the progression of the disease as well as the lives of patients.
A working group at the Walther Straub Institute for Pharmacology and Toxicology at LMU Munich is investigating TRP proteins as target structures for new drugs.
How can chronic lung diseases in babies be diagnosed earlier and better? DZL researchers in Munich and Giessen are on the trail of three promising proteins.
At the Asklepios Clinic in Gauting, the biobank team collects samples from patients with lung diseases – indispensable substances for science.